Poor peripheral blood stem cell mobilization affects long‐term outcomes in multiple myeloma patients undergoing autologous stem cell transplantationJan S. Moreb, Jack W. Hsu, John R. Wingard et al.|Journal of Clinical Apheresis|2017Cited by 43
Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemiaMaxim Norkin, John R. Wingard, Lakshmikanth Katragadda et al.|Blood Cancer Journal|2017Cited by 26
Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDSLeylah Drusbosky, Christopher R. Cogle, Elizabeth Wise et al.|Blood|2016Cited by 2
Low Frequency of Second Autologous STEM CELL Transplantation (ASCT) for Multiple Myeloma (MM) Patients (PTS) Aged 65 YEARS and ABOVE in the Modern EraPrajwol Pathak, Maxim Norkin, Fei Zou et al.|Transplantation and Cellular Therapy|2016Cited by 0
Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple MyelomaPrajwol Pathak, Maxim Norkin, Athira Unnikrishnan et al.|Blood|2016Cited by 0